Tacrolimus long-acting injectable - MedinCell
Alternative Names: mdc-GRTLatest Information Update: 13 Nov 2023
At a glance
- Originator MedinCell S.A.
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Transplant rejection